IP Library Granted Patent US 9,193,778
Granted Patent B2
US 9,193,778 · App. 13/511,353 · Granted Nov 24, 2015

T cell receptors specific for immunodominant CTL epitopes of HCV

Inventor: Margaret Sällberg Chen (Stockholm, SE)
Assignee: Tripep AB
C07K14/7051A01K2207/15A01K2227/105A01K2267/0387A61K38/00C12N2740/13043C12N2770/24211
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,193,778
App. No.
13/511,353
Granted
Nov 24, 2015
Kind
B2
Abstract

The present invention relates generally to the field of immunology. More particularly, aspects of the invention concern the discovery of several T cell receptors (TCRs) that are specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, methods of making TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) proliferation.

Claims (25)

1. An isolated nucleic acid comprising a sequence encoding a peptide that comprises the sequence of SEQ ID NO:1, wherein said isolated nucleic acid is codon-optimized for expression in humans.

2. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:76.

3. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:78.

4. An isolated cell comprising the isolated nucleic acid of claim 1 .

5. The isolated cell of claim 4 , wherein said isolated nucleic acid comprises SEQ ID NO:63.

6. The isolated cell of claim 4 , wherein the peptide that comprises the sequence of SEQ ID NO: 1 comprises the sequence of SEQ ID NO:72.

7. The isolated cell of claim 4 , wherein said isolated nucleic acid comprises SEQ ID NO:74.

8. The isolated cell of claim 4 , wherein said isolated nucleic acid comprises SEQ ID NO:76.

9. The isolated cell of claim 4 , wherein said isolated nucleic acid comprises SEQ ID NO:78.

10. A host-expression vector comprising the isolated nucleic acid of claim 1 .

11. The host-expression vector of claim 10 , wherein said isolated nucleic acid comprises SEQ ID NO:63.

12. The host-expression vector of claim 10 , wherein said peptide that comprises the sequence of SEQ ID NO:1 comprises the sequence of SEQ ID NO:72.

13. The host expression vector of claim 12 , wherein said isolated nucleic acid comprises SEQ ID NO:74.

14. The host-expression vector of claim 12 , wherein said isolated nucleic acid comprises SEQ ID NO:76.

15. The host-expression vector of claim 12 , wherein said isolated nucleic acid comprises SEQ ID NO:78.

16. The isolated nucleic acid of claim 1 , wherein said nucleic acid further comprises a nucleic acid sequence encoding a peptide that comprises the sequence of SEQ ID NO:2.

17. The isolated nucleic acid of claim 16 , wherein said isolated nucleic acid comprises SEQ ID NO:64.

18. The isolated nucleic acid of claim 16 , wherein the sequence that encodes SEQ ID NO:2 encodes SEQ ID NO:73.

19. The isolated nucleic acid of claim 18 , wherein said isolated nucleic acid comprises SEQ ID NO:75.

20. The isolated nucleic acid of claim 16 , wherein said isolated nucleic acid comprises SEQ ID NO:77.

21. The isolated nucleic acid of claim 16 , wherein said isolated nucleic acid comprises SEQ ID NO:79.

22. The isolated nucleic acid of claim 16 , wherein the isolated nucleic acid that encodes SEQ ID NO: 1 and that encodes SEQ ID NO:2 further encodes a 2A protease cleavage site positioned between SEQ ID NO: 1 and SEQ ID NO:2.

23. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:63.

24. The isolated nucleic acid of claim 1 , wherein said peptide that comprises the sequence of SEQ ID NO:1 comprises the sequence of SEQ ID NO:72.

25. The isolated nucleic acid of claim 1 , wherein said isolated nucleic acid comprises SEQ ID NO:74.

Assignments (3)
SECURITY INTEREST Recorded Sep 29, 2015
From: TRIPEP AB
To: KNOBBE, MARTENS, OLSON & BEAR, LLP
Reel/Frame 036714/0719 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 16, 2014
From: CHRONTECH PHARMA AB
To: TRIPEP AB
Reel/Frame 034521/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 27, 2012
From: CHEN, MARGARET SALLBERG
To: CHRONTECH PHARMA AB
Reel/Frame 028851/0546 →
Continuity (2)
Provisional Application 61264155 · Nov 24, 2009
Related Publication 20130011375A1 · Jan 10, 2013